Le Lézard
Classified in: Health, Business
Subjects: NPT, TDS, LIC, JVN

BostonSight® Announces International Partnership


NEEDHAM, Mass., Oct. 3, 2017 /PRNewswire/ -- BostonSight®, a nonprofit international leader in the treatment of patients with ocular surface disease, and the LV Prasad Eye Institute (LVPEI), a non-profit, non-government eye care institution located in Hyderabad, India, whose mission is to "Prevent blindness and provide vision rehabilitation", announced a global partnership to manufacture and distribute BostonSight scleral contact lenses. 

LVPEI will manufacture and distribute BostonSight scleral lenses to ophthalmologists and optometrists to prescribe to their patients in India, South East Asia, the Middle East and Africa. This is the first time that BostonSight® PROSE (prosthetic replacement of the ocular surface ecosystem), and BostonSight SCLERAL lenses will be fabricated outside of the United States. Both organizations serve and subsidize under-privileged populations who benefit from access to this unique treatment solution that oftentimes is the only vision impairment alleviation for a variety of ocular surface disorders.

The World Health Organization estimates a Global visual impairment population in excess of 450 million people. Those who suffer from mild, moderate and severe visual impairment experience significant reduction in quality of life, and the ability to lead productive lifestyles.

BostonSight CEO, Gene Guselli, and LVPEI Founder and Chairman, Dr. Gullapalli N. Rao, jointly announced the Partnership at the International Association of Contact Lens Educators (IACLE) 2017 Congress and the World Congress of Optometry in Hyderabad, India in mid-September. 

Mr. Guselli said, "This partnership creates an opportunity for us to combine our collective expertise and provide affordable access to visually impaired, underserved populations around the world.  We are privileged to work with LV Prasad to make this a reality."

This expanded relationship with LVPEI brings our treatment solutions to millions of patients throughout the world, and furthers BostonSight's mission "To improve the quality of life for patients and their families by transforming the understanding, treatment and care of the ocular surface."

About BostonSight:

BostonSight is an internationally renowned nonprofit eye healthcare organization with a mission to improve the quality of life for patients and their families by transforming the understanding, treatment and care of the ocular surface. For more information, visit www.bostonsight.org.

About LV Prasad Eye Institute:

The LV Prasad Eye Institute (LVPEI) was established in 1986-87 at Hyderabad as a not-for-profit, non-government, public-spirited, comprehensive eye care institution.  For more information, please visit:  www.lvpei.org.

Media Contact:   
Tara Stepanian
Media Relations 
BostonSight  
781-726-7526 (office)            
[email protected]

Information:  www.bostonsight.org

SOURCE BostonSight


These press releases may also interest you

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...



News published on and distributed by: